Today NIH announced the launch of #ACTIV-2 (outpatient) Phase 2/3 and ACTIV-3 (inpatient) Phase 3 clinical trials investigating the use of monoclonal antibodies as a potential treatment for #COVID19. Antibodies are molecules our immune systems use to fight germs. People recovered from #COVID19 can produce antibodies. Researchers can examine blood samples from COVID-19 survivors & isolate antibodies. Scientists then create lab-engineered copies, thus making monoclonal antibodies. | National Insti

14K views · 281 reactions | Neutralizing monoclonal antibodies (mAbs) may be a highly effective way to treat and prevent COVID-19 while awaiting a vaccine. This video explains how these drugs are created and how they target the SARS-CoV-2 virus. National Institutes of Health (NIH) & UNC Institute for Global Health and Infectious Diseases | JAMA | Facebook